Application of nucleoside compounds in the preparation of drugs with anti-intoxication and hangover-relief effects

Abstract

This invention relates to the field of pharmaceutical technology, specifically to the application of nucleoside compounds in the preparation of medicines with anti-drunkenness and hangover-relieving functions. The nucleoside compounds specifically include cytosine nucleoside, cytosine nucleotide, and lamivudine. Experimental results show that cytosine nucleoside, cytosine nucleotide, and lamivudine can significantly prolong the time required for the loss of righting reflex and shorten the time required for the recovery of righting reflex. That is, cytosine nucleoside, cytosine nucleotide, and lamivudine all have the effect of preventing drunkenness and accelerating sobering up, providing a new use for cytosine nucleoside, cytosine nucleotide, and lamivudine.

Description

Technical Field

[0001] The present invention relates to the field of medical technology, and in particular to the application of nucleoside compounds in the preparation of drugs with the effects of preventing drunkenness and sobering up. Background Art

[0002] At present, the alcohol-relieving drugs independently developed in my country are mainly based on compositions. For example, patent (CN102038867B) discloses an alcohol-relieving composition, and its raw materials include: a mixture of one or more of S-adenosylmethionine or cysteine ​​or methionine, one or a mixture of D-glyceric acid or D-glycerate, a mixture of one or more of succinic acid or husoric acid or citric acid or oxaloacetic acid or malic acid, a mixture of one or more of vitamin B1 or vitamin B6 or vitamin B2, one or a mixture of coenzyme Q10 or coenzyme I, L-glutamine, Perilla frutescens, Artemisia capillaris, white peony root and hawthorn leaf. Patent (CN106492110B) also discloses an alcohol-relieving composition, comprising the following components: maca extract, kudzu root extract, turmeric extract and Hovenia dulcis extract. However, no single-component alcohol-relieving drug has been developed.

[0003] Cytosine nucleoside is one of the pyrimidine nucleosides that constitute nucleic acids. It is composed of cytosine and ribose. It is an essential compound for life and a very important drug synthesis intermediate in contemporary medicine. It has no clear medical use in clinical practice. Cytosine nucleotide is one of the pyrimidine nucleotides and a component of RNA. It has no clear medical use in clinical practice. Lamivudine is a nucleoside analog that competitively inhibits the synthesis and extension of viral DNA chains. It is mainly used to treat hepatitis B and hepatobiliary diseases.

[0004] The inventors accidentally discovered during the experiment that cytosine nucleoside, cytosine nucleotide and lamivudine have the functions of preventing alcohol intolerance, alcohol intoxication, alcohol poisoning and accelerating sobering up, which provides new uses for cytosine nucleoside, cytosine nucleotide and lamivudine. Summary of the invention

[0005] In view of the above problems, the present invention provides a use of a nucleoside compound in the preparation of a drug for treating and / or preventing drunkenness and hangover. The nucleoside compound is cytosine nucleoside, cytosine nucleotide and lamivudine. The structural formula of the cytosine nucleoside is shown in formula (I), the structural formula of lamivudine is shown in formula (II), and the structure of the cytosine nucleotide is shown in formula (III):

[0006]

[0007] The second object of the present invention is to provide a nucleoside compound for use in preparing a drug for treating and / or preventing alcohol poisoning, alcohol-induced death or drinking complications, wherein the nucleoside compound is cytosine nucleoside, cytosine nucleotide or lamivudine, wherein the structural formula of the cytosine nucleoside is as shown in formula (I), the structural formula of the lamivudine is as shown in formula (II), and the structure of the cytosine nucleotide is as shown in formula (III):

[0008]

[0009] Preferably, the drug is added to a pharmaceutically acceptable carrier to be prepared into powders, tablets, granules, capsules, solutions, emulsions, suspensions, and injections.

[0010] Preferably, the drug is added to a pharmaceutically acceptable carrier to be prepared into tablets or capsules.

[0011] Preferably, the drug is taken sublingually or swallowed.

[0012] Preferably, the drug having the effect of preventing drunkenness and sobering up is taken before and / or after drinking.

[0013] The beneficial effects of the present invention are as follows: the present invention provides a new use of a nucleoside compound in the preparation of a drug with the effects of preventing drunkenness and sobering up, wherein the nucleoside compound is cytosine nucleoside, cytosine nucleotide and lamivudine, and the experimental results show that: (1) cytosine nucleoside has the effect of preventing drunkenness; the dosage of the cytosine nucleoside group is 1 / 5 of the dosage of the positive control group RU21, that is, cytosine nucleoside achieves the same effect of preventing drunkenness as the positive control group RU21 Antipu compound tablet at a lower dosage; (2) cytosine nucleoside has The dosage of the cytosine nucleoside group was 1 / 5 of that of the positive control group RU21, that is, cytosine nucleoside achieved the same effect of accelerating sobering up as the positive control group RU21 Antipu compound tablets at a lower dosage; (3) cytosine nucleoside has the effect of inhibiting alcohol-induced mortality; the dosage of the cytosine nucleoside group was 1 / 5 of that of the positive control group RU21, that is, cytosine nucleoside achieved the same effect of inhibiting alcohol-induced mortality as the positive control group RU21 Antipu compound tablets at a lower dosage. (4) Lamivudine has the effect of preventing drunkenness; the dosage of the lamivudine group is 1 / 25 of the dosage of RU21 in the positive control group, that is, lamivudine has a better effect of preventing drunkenness at a lower dosage than the positive control group RU21 Antipu compound tablet; (5) Lamivudine has the effect of accelerating sobering up; compared with the model group, the lamivudine group can significantly shorten the time required for the recovery of the righting reflex of mice, indicating that lamivudine has the effect of accelerating sobering up; at the same time, the dosage of the lamivudine group is 1 / 25 of the dosage of RU21 in the positive control group, that is, lamivudine has a better effect of accelerating sobering up at a lower dosage than the positive control group RU21 Antipu compound tablet. (6) Lamivudine has the effect of inhibiting alcohol-induced death; the dosage of the lamivudine group is 1 / 25 of the dosage of RU21 in the positive control group, that is, lamivudine has the same effect of inhibiting alcohol-induced death as the positive control group RU21 Antipu compound tablet at a lower dosage. (7) Cytosine nucleotide has the effect of preventing drunkenness; the dosage of the cytosine nucleotide group is 100 mg / kg lower than that of the positive drug group RU21, that is, the cytosine nucleotide has the same effect of preventing drunkenness as the positive control group RU21 at a lower dosage; (8) Cytosine nucleotide has the effect of accelerating sobering up; the dosage of the cytosine nucleotide group is 100 mg / kg lower than that of the positive drug group RU21, that is, the cytosine nucleotide has the same effect of accelerating sobering up as the positive control group RU21 at a lower dosage; (9) Cytosine nucleotide has the effect of inhibiting alcohol-induced mortality; the dosage of the cytosine nucleotide group is 100 mg / kg lower than that of the positive drug group RU21, that is, the cytosine nucleotide has the same effect of inhibiting mortality as the positive control group RU21 Antipu compound tablets at a lower dosage. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 The present invention provides a bar graph of the time required for the righting reflex to disappear in each administration group of mice;

[0015] Among them, "Control" is the blank control group without alcohol intervention, "Model" is the model control group with one-time excessive alcohol intervention, "RU21" is the positive control RU21 Antipu compound tablet group, and "Cytidine" is the cytidine nucleoside group. Compared with the positive control group RU21 Antipu compound tablet, ns>0.05.

[0016] Figure 2 The present invention provides a bar graph of the time required for the righting reflex to recover in each administration group of mice;

[0017] Among them, "Control" refers to the group without alcohol intervention, "Model" refers to the control group of the one-time excessive alcohol intervention model, "RU21" refers to the positive control RU21 Antipu compound tablet group, and "Cytidine" refers to the cytidine nucleoside group. Compared with the positive control group RU21 Antipu compound tablet, ns>0.05.

[0018] Figure 3 The present invention provides a histogram of the mortality rate of mice in each drug administration group 24 hours after drinking;

[0019] Among them, "Control" refers to the group without alcohol intervention, "Model" refers to the control group of the one-time excessive alcohol intervention model, "RU21" refers to the positive control RU21 Antipu compound tablet group, and "Cytidine" refers to the cytidine nucleoside group. Compared with the positive control RU21 Antipu compound tablet group, there was no difference.

[0020] Figure 4 The present invention provides a bar graph of the time required for the righting reflex to disappear in each administration group of mice;

[0021] Among them, "Control" is the blank control group without alcohol intervention, "Model" is the model control group with one-time excessive alcohol intervention, "RU21" is the positive control RU21 Antipu compound tablet group, and "Lamivudine" is the lamivudine group. Compared with the one-time excessive alcohol intervention model group "Model", ***p<0.001; compared with the positive control RU21 Antipu compound tablet group, ***p<0.001.

[0022] Figure 5 The present invention provides a bar graph of the time required for the righting reflex to recover in each administration group of mice;

[0023] Among them, "Control" refers to the group without alcohol intervention, "Model" refers to the control group of the one-time excessive alcohol intervention model, "RU21" refers to the positive control RU21 Antipu compound tablet group, and "Lamivudine" refers to the lamivudine group. Compared with the one-time excessive alcohol intervention model group "Control", ***p<0.001; compared with the positive control RU21 Antipu compound tablet group, *p<0.05. Figure 6 The present invention provides a histogram of the mortality rate of mice in each drug administration group 24 hours after drinking;

[0024] Among them, "Control" refers to the group without alcohol intervention, "Model" refers to the control group of the one-time excessive alcohol intervention model, "RU21" refers to the positive control RU21 Antipu compound tablet group, and "Lamivudine" refers to the cytosine nucleoside group. Compared with the positive control RU21 Antipu compound tablet group, there is no difference.

[0025] Figure 7 The present invention provides a bar graph of the time required for the righting reflex to disappear in each administration group of mice;

[0026] Among them, "Control" is the blank control group without alcohol intervention, "Model" is the model control group with one-time excessive alcohol intervention, "RU21" is the positive control RU21 Antipu compound tablet group, and "5'-CMP" is the cytosine nucleotide group. Compared with the positive control RU21 Antipu compound tablet group, ns>0.05.

[0027] Figure 8 The present invention provides a bar graph of the time required for the righting reflex to recover in each administration group of mice;

[0028] Among them, "Control" refers to the group without alcohol intervention, "Model" refers to the control group of the one-time excessive alcohol intervention model, "RU21" refers to the positive control RU21 Antipu compound tablet group, and "5'-CMP" refers to the cytosine nucleotide group. Compared with the positive control RU21 Antipu compound tablet group, ns>0.05.

[0029] Fig. 9 The present invention provides a histogram of the mortality rate of mice in each drug administration group 24 hours after drinking;

[0030] Among them, "Control" is the group without alcohol intervention, "Model" is the control group of the one-time excessive alcohol intervention model, "RU21" is the positive control RU21 Antipu compound tablet group, and "5'-CMP" is the cytosine nucleotide group. Compared with the positive control RU21 Antipu compound tablet group, there is no difference. DETAILED DESCRIPTION

[0031] The following will be combined with the drawings in the examples of the present invention to clearly and completely describe the technical solutions in the examples of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments, and at the same time protect the therapeutic effects of cytosine nucleoside, cytosine nucleotide and lamivudine on all symptoms after alcohol intervention, including different dosage forms, dosages, etc. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative labor are within the scope of protection of the present invention.

[0032] It should be understood that the above brief description and the following detailed description are exemplary and are only used for explanation, and do not limit the subject matter of the invention herein. In this application, it must be noted that unless otherwise clearly stated in the text, the singular forms used in this specification and claims include the plural forms of the referred things. It should also be noted that unless otherwise stated, the use of "or" and "or" means "and / or". In addition, the use of the term "including" and other forms, such as "including", "containing" and "containing" are not restrictive.

[0033] The "RU21 Antipu composite tablets" described in the present invention are produced by Spirit Sciences of the United States and are now recognized worldwide as the best hangover sobering product.

[0034] Example 1: Study on the effect of cytosine nucleoside in preventing drunkenness, accelerating sobering up and inhibiting death caused by alcohol

[0035] 1. Experimental Animals

[0036] Four-week-old SPF male Kunming mice were selected, with a body weight of 22±2g. They were provided by the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences. No drugs were used before the experiment. The experimental animals were acclimatized for one week in an environment with a temperature of 24-26°C and a 12h / 12h day-night cycle. The animals were given diet and free access to water, and then divided into groups for the experiment.

[0037] 2. Drugs and reagents

[0038] Cytidine (HPLC ≥ 99%), purchased from Aladdin Biotechnology Co., Ltd., batch number: C100358, molecular weight: 243.22;

[0039] RU21 Antipro composite tablets, purchased from Spirit Science USA, batch number: 25794;

[0040] Anhydrous ethanol was purchased from Tianjin Fuyu Fine Chemicals Co., Ltd., batch number: November 8, 2020.

[0041] 3. Experimental groups and intragastric administration dose

[0042] Thirty-six male 4-week-old Kunming mice were randomly divided into 4 groups: blank control group (Control), model control group (Model), positive control group (RU21), and cytidine group (Cytidine), with 9 mice in each group.

[0043] 4. Experimental Methods

[0044] 36 Kunming mice were grouped as described above. After fasting for 12 hours before the experiment, the blank control group (Control) and the model group (Model) were gavaged with an equal volume of normal saline, the positive control group (RU21) was gavaged with RU21 Antipu compound tablets at a dose of 500 mg / kg, and the cytidine group (Cytidine) was gavaged with cytidine at a dose of 100 mg / kg. 30 minutes after gavage, except for the blank control group (Control) which was gavaged with an equal volume of double distilled water, the other three groups were gavaged with 60% alcohol at a dose of 0.16 mL / 10 g, and the timing was started immediately to record and calculate the time required for the righting reflex to disappear, the duration of the righting reflex to recover, and the survival rate of mice in each group 24 hours after drinking.

[0045] 5. Experimental Results

[0046] (1) The time required for the righting reflex of mice to disappear

[0047] like Figure 1 As shown in the figure, compared with the blank control group, the time required for the righting reflex of mice in the model group was shorter, which was consistent with the drunkenness model after excessive drinking, indicating that the model was successfully constructed. Compared with the positive control group, the effect of cytosine nucleoside in prolonging the time required for the righting reflex of mice was not significantly different from that of the positive control RU21 Antipu compound tablet group (ns>0.05), indicating that cytosine nucleoside and the positive control RU21 Antipu compound tablet have the same effect in preventing drunkenness. However, in this experiment, the dosage of the positive control group was 500 mg / kg, and the dosage of the cytosine nucleoside group was 100 mg / kg, which was 1 / 5 of the dosage of the positive control group. In other words, cytosine nucleoside achieved the same effect of preventing drunkenness as the positive control RU21 Antipu compound tablet at a lower dosage.

[0048] (2) The time required for the righting reflex of mice to recover

[0049] like Figure 2As shown, compared with the positive control group, the effect of cytosine nucleoside in shortening the time required for the recovery of the righting reflex of mice was not significantly different from that of the positive control RU21 Antipu compound tablet group (ns>0.05), indicating that cytosine nucleoside and the positive control RU21 Antipu compound tablet have the same effect of accelerating sobering up. However, in this experiment, the dosage of the positive control group was 500 mg / kg, and the dosage of the cytosine nucleoside group was 100 mg / kg, which was 1 / 5 of that of the positive control group. In other words, cytosine nucleoside achieved the same effect of accelerating sobering up as the positive control RU21 Antipu compound tablet at a lower dosage.

[0050] (3) Survival rate of mice in each group 24 hours after drinking

[0051] like Figure 3 As shown, compared with the model group, cytosine nucleoside has the effect of inhibiting alcohol-induced mortality within 24 hours after drinking; compared with the positive control group, within 24 hours after drinking, the effect of cytosine nucleoside in inhibiting alcohol-induced mortality was not significantly different from the positive control RU21 Antipu compound tablets (ns>0.05). However, in this experiment, the dosage of the positive control group was 500 mg / kg, and the dosage of the cytosine nucleoside group was 100 mg / kg, which was 1 / 5 of the dosage of the positive control group. In other words, cytosine nucleoside achieved the same effect of inhibiting alcohol-induced mortality as the positive control RU21 Antipu compound tablets at a lower dosage. Example 2: Study on the effect of lamivudine in preventing drunkenness, accelerating sobering up, and inhibiting alcohol-induced mortality

[0052] 1. Experimental Animals

[0053] Four-week-old SPF male Kunming mice were selected, with a body weight of 22±2g. They were provided by the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences. No drugs were used before the experiment. The experimental animals were acclimatized for one week in an environment with a temperature of 24-26°C and a 12h / 12h day-night cycle. The animals were given diet and free access to water, and then divided into groups for the experiment.

[0054] 2. Drugs and reagents

[0055] Lamivudine (HPLC ≥ 98%), purchased from MacLean Biotechnology Co., Ltd., batch number: C10102050, molecular weight: 229.25;

[0056] RU21 Antipro composite tablets, purchased from Spirit Science USA, batch number: 25794;

[0057] Anhydrous ethanol was purchased from Tianjin Fuyu Fine Chemicals Co., Ltd., batch number: November 8, 2020.

[0058] 3. Experimental groups and intragastric administration dose

[0059] Thirty-six male 4-week-old Kunming mice were randomly divided into 4 groups: blank control group (Control), model control group (Model), positive control group (RU21), and lamivudine group (Lamivudine), with 9 mice in each group.

[0060] 4. Experimental Methods

[0061] 36 Kunming mice were grouped as described above. After fasting for 12 hours before the experiment, the blank control group (Control) and the model group (Model) were gavaged with an equal volume of normal saline, the positive control group (RU21) was gavaged with RU21 Antipu compound tablets at a dose of 500 mg / kg, and the lamivudine group (Lamivudine) was gavaged with lamivudine at a dose of 20 mg / kg. 30 minutes after the gavage, except for the blank control group (Control) which was gavaged with an equal volume of double distilled water, the other three groups were gavaged with 60% alcohol at a dose of 0.16 mL / 10 g, and the timing was immediately started to record the duration of the disappearance and recovery of the righting reflex of each group of mice.

[0062] 5. Experimental Results

[0063] (1) The time required for the righting reflex of mice to disappear

[0064] like Figure 4 As shown, compared with the blank control group, the time required for the righting reflex of mice in the model group was shorter, which was consistent with the drunkenness model after excessive drinking, indicating that the model was successfully constructed. Compared with the model group, lamivudine can significantly prolong the time required for the righting reflex of mice to disappear (***p<0.001), indicating that lamivudine has the effect of preventing drunkenness. Compared with the positive control RU21 Antipu compound tablet group, lamivudine can significantly prolong the time required for the righting reflex of mice to disappear (***p<0.001), indicating that lamivudine is more effective in preventing drunkenness than RU21 Antipu compound tablets.

[0065] (2) The time required for the righting reflex of mice to recover

[0066] like Figure 5 As shown in the figure, compared with the model group, lamivudine can significantly shorten the time required for the righting reflex to recover in mice (***p<0.001), indicating that lamivudine has the effect of accelerating sobering up. Compared with the positive control RU21 Antipu compound tablet group, lamivudine can significantly shorten the time required for the righting reflex to recover in mice (*p<0.05), indicating that lamivudine is better than RU21 Antipu compound tablet in accelerating sobering up.

[0067] (3) Survival rate of mice in each group 24 hours after drinking

[0068] like Figure 6 As shown, compared with the model group, lamivudine had the effect of inhibiting alcohol-induced mortality within 24 hours after drinking; compared with the positive control RU21 Antipu compound tablets group, there was no significant difference in the effect of lamivudine on inhibiting alcohol-induced mortality within 24 hours after drinking (ns>0.05).

[0069] Example 3: Study on the effect of cytosine nucleotides in preventing drunkenness and accelerating sobering up

[0070] 1. Experimental Animals

[0071] Four-week-old SPF male Kunming mice were selected, with a body weight of 22±2g. They were provided by the Lanzhou Veterinary Research Institute of the Chinese Academy of Agricultural Sciences. No drugs were used before the experiment. The experimental animals were acclimatized for one week in an environment with a temperature of 24-26°C and a 12h / 12h day-night cycle. The animals were given diet and free access to water, and then divided into groups for the experiment.

[0072] 2. Drugs and reagents

[0073] Cytidine-5 ， -monophosphate, HPLC ≥ 98%), purchased from Aladdin Biotechnology Co., Ltd., batch number: J1831067, molecular weight: 323.20;

[0074] RU21 Antipro composite tablets, purchased from Spirit Science USA, batch number: 25794;

[0075] Anhydrous ethanol was purchased from Tianjin Fuyu Fine Chemicals Co., Ltd., batch number: November 8, 2020.

[0076] 3. Experimental groups and intragastric administration dose

[0077] Forty male 4-week-old Kunming mice were randomly divided into 4 groups: blank control group (Control), model control group (Model), positive control group (RU21), and cytosine nucleotide group (5'-CMP), with 10 mice in each group.

[0078] 4. Experimental Methods

[0079] 40 Kunming mice were grouped as described above. After fasting for 12 hours before the experiment, the blank control group (Control) and the model group (Model) were gavaged with an equal volume of normal saline, the positive control group (RU21) was gavaged with RU21 Antipu compound tablets at a dose of 500 mg / kg, and the cytosine nucleotide group (5'-CMP) was gavaged with a dose of 400 mg / kg. 30 minutes after gavage, except for the blank control group (Control) which was gavaged with an equal volume of double distilled water, the other three groups were gavaged with 60% alcohol at a dose of 0.16 mL / 10 g, and the timing was immediately started to record the duration of the disappearance of the righting reflex and the recovery of the righting reflex of each group of mice.

[0080] 5. Experimental Results

[0081] (1) The time required for the righting reflex of mice to disappear

[0082] like Figure 7 As shown in the figure, compared with the blank control group, the time required for the righting reflex of mice in the model group to disappear was shorter, which was consistent with the drunkenness model after excessive drinking, indicating that the model was successfully constructed. Compared with the model group, cytosine nucleotides can significantly prolong the time required for the righting reflex of mice to disappear, indicating that cytosine nucleotides have the effect of preventing drunkenness; at the same time, compared with the positive control group, cytosine nucleotides prolong the time required for the righting reflex of mice to disappear longer, and there is no significant difference between the groups (ns>0.05). However, in this experiment, the dosage of the positive control RU21 Antipu compound tablet group was 500 mg / kg, and the dosage of the cytosine nucleotide group was 400 mg / kg, which was 100 mg / kg lower than the dosage of the positive control RU21 Antipu compound tablet group. In other words, cytosine nucleotides achieved the same effect of preventing drunkenness as the positive control RU21 Antipu compound tablet at a lower dosage.

[0083] (2) The time required for the righting reflex of mice to recover

[0084] like Figure 8 As shown, compared with the model group, the cytosine nucleotide group was able to shorten the time required for the recovery of the righting reflex of mice, indicating that cytosine nucleotide has the effect of accelerating sobering up; compared with the positive control RU21 Antipu compound tablet group, there was no significant difference in the shortening of the time required for the recovery of the righting reflex of mice in the cytosine nucleotide group (ns>0.05), but in this experiment, the dosage of the positive control RU21 Antipu compound tablet group was 500 mg / kg, and the dosage of the cytosine nucleotide group was 400 mg / kg, which was 100 mg / kg lower than that of the positive control RU21 Antipu compound tablet group. In other words, cytosine nucleotide achieved the same effect of accelerating sobering up as the positive control group RU21 Antipu compound tablet at a lower dosage.

[0085] (3) Survival rate of mice after drinking

[0086] like Figure 3 As shown, compared with the model group, the cytosine nucleotide group was able to inhibit the death of mice caused by a single excessive drinking, indicating that cytosine nucleotide has the effect of inhibiting death caused by excessive drinking; compared with the positive control group, the cytosine nucleotide group had the same effect of inhibiting the death of mice caused by a single excessive drinking, but in this experiment, the dosage of the positive control RU21 Antipu compound tablet group was 500 mg / kg, and the dosage of the cytosine nucleotide group was 400 mg / kg, which was 100 mg / kg lower than that of the positive control RU21 Antipu compound tablet group. In other words, cytosine nucleotide achieved the same effect of inhibiting death as the positive control group RU21 Antipu compound tablet at a lower dosage.

[0087] In summary, the present invention uses a one-time excessive alcohol intake animal model to evaluate the therapeutic effects of cytidine nucleoside, cytosine nucleotide and lamivudine on preventing drunkenness, accelerating sobering up and inhibiting alcohol-induced death, and confirms that cytidine nucleoside, cytosine nucleotide and lamivudine have the effects of preventing drunkenness, accelerating sobering up and inhibiting alcohol-induced death.

[0088] Any technical solutions obtained by technicians through logical analysis, inference and experiments on the prior art according to the ideas of the present invention shall fall within the scope of protection in the claims.

Claims

1. The use of nucleoside compounds in the preparation of drugs for preventing drunkenness and sobering up, characterized in that: The nucleoside compound is lamivudine, and the structural formula of lamivudine is shown in formula (I):

2. Use of a nucleoside compound in the preparation of a drug for treating and / or preventing alcohol poisoning or alcohol-induced death, characterized in that: The nucleoside compound is lamivudine, and the structural formula of lamivudine is shown in formula (I):

3. The use according to claim 1, characterized in that The drug is added to a pharmaceutically acceptable carrier and prepared into powder, tablet, granule, capsule, solution, emulsion, suspension and injection.

4. The use according to claim 3, characterized in that The drug is added into a pharmaceutically acceptable carrier to prepare tablets and capsules.

5. The use according to claim 4, characterized in that The medicine is taken sublingually or by swallowing.

6. The use according to claim 1, characterized in that The medicine with the effects of preventing drunkenness and sobering up is taken before and / or after drinking.

Images